Jul 23, 2026
A two-day meeting reviews nominated peptide substances including BPC-157 for possible use in pharmacy compounding.
The debate reflects public interest in recovery and longevity peptides. Advisory consideration and compounding-list decisions are not FDA approval of a drug’s safety and effectiveness.